Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 [Yahoo! Finance]
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference